Table 1.
Patient characteristics.
| Parameter | All AML samples | NPM1-mutated AML | NPM1 wild-type AML | Bone marrow donors |
|---|---|---|---|---|
| N | 1251 | 386 | 865 | 236 |
| Age, median (IQR) | 57 (38–67) | 57 (49–66) | 54 (38–64) | 31 (25–39) |
| Sex, n (%) | ||||
| Male | 668 (53.4) | 173 (44.8) | 495 (57.2) | 70 |
| Female | 583 (46.6) | 213 (55.2) | 370 (42.8) | 30 |
| AML type, n (%) | ||||
| De novo | 969 (77.7) | 339 (88.3) | 630 (73) | / |
| sAML | 177 (14.2) | 24 (6.2) | 153 (17.7) | / |
| tAML | 101 (8.1) | 21 (5.5) | 80 (9.3) | / |
| ELN2017 risk, n (%) | ||||
| Favorable | 380 (33) | 277 (78) | 111 (13.8) | / |
| Intermediate | 521 (45.3) | 75 (21.1) | 446 (55.5) | / |
| Adverse | 249 (21.7) | 3 (0.8) | 246 (30.6) | / |
| PB blasts, median (IQR) | 23.5 (4–60) | 38 (11–72.5) | 18 (2–51) | / |
| BM blasts, median (IQR) | 60.5 (40–80) | 73.5 (54–85) | 54 (37–75) | / |
Patient characteristics for the AML and control (bone marrow donors) cohort. The AML cohort is further subdivided by NPM1 mutation status. AML type was defined according to the WHO 2016 classification. sAML secondary AML, tAML therapy-associated AML, PB peripheral blood, BM bone marrow, N/n number, IQR interquartile range.